{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T22:38:09Z","timestamp":1788043089482,"version":"build-2784847793"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2023,8,21]],"date-time":"2023-08-21T00:00:00Z","timestamp":1692576000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,8,21]],"date-time":"2023-08-21T00:00:00Z","timestamp":1692576000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"NIH","award":["R01 CA114037"],"award-info":[{"award-number":["R01 CA114037"]}]},{"name":"NIH","award":["R01 CA184968"],"award-info":[{"award-number":["R01 CA184968"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1007\/s00280-023-04578-9","type":"journal-article","created":{"date-parts":[[2023,8,21]],"date-time":"2023-08-21T06:02:37Z","timestamp":1692597757000},"page":"369-380","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["A clinical trial of zosuquidar plus gemtuzumab ozogamicin (GO) in relapsed or refractory acute myeloid leukemia (RR AML): evidence of efficacy based on leukemic blast P-glycoprotein functional phenotype"],"prefix":"10.1007","volume":"92","clinical-trial-number":[{"clinical-trial-number":"nct00233909","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1053-9483","authenticated-orcid":false,"given":"John F.","family":"Marcelletti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6814-2070","authenticated-orcid":false,"given":"Branimir I.","family":"Sikic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,8,21]]},"reference":[{"issue":"2","key":"4578_CR1","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1097\/MOH.0000000000000561","volume":"27","author":"K Koenig","year":"2020","unstructured":"Koenig K, Mims A (2020) Relapsed or primary refractory AML: moving past MEC and FLAG-ida. Curr Opin Hematol 27(2):108\u2013114. https:\/\/doi.org\/10.1097\/MOH.0000000000000561","journal-title":"Curr Opin Hematol"},{"issue":"5","key":"4578_CR2","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1038\/leu.2017.22","volume":"31","author":"RF Schlenk","year":"2017","unstructured":"Schlenk RF, Frech P, Weber D et al (2017) Impact of pretreatment characteristics and salvage strategy on outcome in patients with relapsed acute myeloid leukemia. Leukemia 31(5):1217\u20131220. https:\/\/doi.org\/10.1038\/leu.2017.22","journal-title":"Leukemia"},{"issue":"7","key":"4578_CR3","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/s41568-018-0005-8","volume":"18","author":"WR Robey","year":"2018","unstructured":"Robey WR, Pluchino KM, Hall MD, Fojo AT, Bates SE, Gottesman MM (2018) Revisiting the role of efflux pumps in multidrug-resistant cancer. Nat Rev Cancer 18(7):452\u2013464. https:\/\/doi.org\/10.1038\/s41568-018-0005-8","journal-title":"Nat Rev Cancer"},{"issue":"7","key":"4578_CR4","doi-asserted-by":"publisher","first-page":"1863","DOI":"10.1158\/1078-0432.CCR-11-1590","volume":"18","author":"KG Chen","year":"2012","unstructured":"Chen KG, Sikic BI (2012) Molecular pathways: regulation and therapeutic implications of multidrug resistance. Clin Cancer Res 18(7):1863\u20131869","journal-title":"Clin Cancer Res"},{"key":"4578_CR5","doi-asserted-by":"publisher","first-page":"4077","DOI":"10.1182\/blood-2010-04-277269","volume":"116","author":"LD Cripe","year":"2010","unstructured":"Cripe LD, Uno H, Paietta EM et al (2010) Zosuquidar, a novel modulator of P-glycoprotein, does not improve the outcome of older patients with newly diagnosed acute myeloid leukemia: a randomized, placebo-controlled, trial of the Eastern Cooperative Oncology Group (ECOG 3999). Blood 116:4077\u20134085","journal-title":"Blood"},{"key":"4578_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cancers11091323","volume":"11","author":"T Boyer","year":"2019","unstructured":"Boyer T, Gonzales F, Barth\u00e9l\u00e9my Marceau-Renaut A et al (2019) Clinical significance of ABCB1 in acute myeloid leukemia: a comprehensive study. Cancers 11:1\u201315. https:\/\/doi.org\/10.3390\/cancers11091323","journal-title":"Cancers"},{"key":"4578_CR7","doi-asserted-by":"publisher","first-page":"4168","DOI":"10.1182\/blood-2006-09-047399","volume":"109","author":"RB Walter","year":"2007","unstructured":"Walter RB, Gooley TA, van der Velden VHJ, Loken MR, van Dongen JJM, Flowers DA, Bernstein ID, Appelbaum FR (2007) CD33 expression and P-glycoprotein\u2013mediated drug efflux inversely correlate and predict clinical outcome in patients with acute myeloid leukemia treated with gemtuzumab ozogamicin monotherapy. Blood 109:4168\u20134170","journal-title":"Blood"},{"key":"4578_CR8","first-page":"854","volume":"290","author":"AH Dantzig","year":"1999","unstructured":"Dantzig AH, Shepard RL, Law KL et al (1999) Selectivity of the multidrug resistance modulator, LY335979, for P-glycoprotein and effect on cytochrome P-450 activities. J Pharmacol Exp Ther 290:854\u2013862","journal-title":"J Pharmacol Exp Ther"},{"key":"4578_CR9","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1002\/ijc.10792","volume":"103","author":"RL Shepard","year":"2003","unstructured":"Shepard RL, Cao J, Starling JJ, Dantzig AH (2003) Modulation of P-glycoprotein but not MRP1- or BCRP-mediated drug resistance by LY335979. Int J Cancer 103:121\u2013125","journal-title":"Int J Cancer"},{"issue":"1","key":"4578_CR10","doi-asserted-by":"publisher","first-page":"39","DOI":"10.2174\/0929867013373903","volume":"8","author":"AH Dantzig","year":"2001","unstructured":"Dantzig AH, Law KL, Cao J, Starling JJ (2001) Reversal of multidrug resistance by the P-glycoprotein modulator, LY335979, from the bench to the clinic. Curr Med Chem 8(1):39\u201350","journal-title":"Curr Med Chem"},{"key":"4578_CR11","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1126\/science.aav7102","volume":"363","author":"A Alam","year":"2019","unstructured":"Alam A, Kowal J, Broude E, Roninson I, Locher KP (2019) Structural insight into substrate and inhibitor discrimination by human P-glycoprotein. Science 363:753\u2013756","journal-title":"Science"},{"key":"4578_CR12","doi-asserted-by":"publisher","first-page":"2320","DOI":"10.1158\/1078-0432.CCR-04-1725","volume":"11","author":"M Qadir","year":"2005","unstructured":"Qadir M, O\u2019Loughlin KL, Fricke SM et al (2005) Cyclosporin A is a broad-spectrum multidrug resistance modulator. Clin Cancer Res 11:2320\u20132326","journal-title":"Clin Cancer Res"},{"issue":"4","key":"4578_CR13","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1046\/j.1365-2141.1998.00870.x","volume":"102","author":"E Wattel","year":"1998","unstructured":"Wattel E, Salary E, Hecquet B et al (1998) Quinine improves the results of intensive chemotherapy in myelodysplastic syndromes expressing P glycoprotein: results of a randomized study. Br J Haematol 102(4):1015\u20131024","journal-title":"Br J Haematol"},{"key":"4578_CR14","doi-asserted-by":"publisher","first-page":"3212","DOI":"10.1182\/blood.V98.12.3212","volume":"98","author":"AF List","year":"2001","unstructured":"List AF, Kopecky KJ, Willman CL et al (2001) Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: A Southwest Oncology Group study. Blood 98:3212\u20133220","journal-title":"Blood"},{"issue":"3","key":"4578_CR15","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1046\/j.1365-2141.2001.02785.x","volume":"113","author":"JA Liu-Yin","year":"2001","unstructured":"Liu-Yin JA, Wheatley K, Rees JK et al (2001) Comparison of \u2018sequential\u2019 versus \u2018standard\u2019 chemotherapy as re-induction treatment, with or without cyclosporine, in refractory\/relapsed acute myeloid leukaemia (AML): results of the UK Medical Research Council AML-R trial. Br J Haematol 113(3):713\u2013726","journal-title":"Br J Haematol"},{"key":"4578_CR16","doi-asserted-by":"publisher","first-page":"3265","DOI":"10.1158\/1078-0432.CCR-03-0644","volume":"10","author":"A Sandler","year":"2004","unstructured":"Sandler A, Gordon M, De Alwis DP et al (2004) A Phase I trial of a potent P-glycoprotein inhibitor, zosuquidar trihydrochloride (LY335979), administered intravenously in combination with doxorubicin in patients with advanced malignancy. Clin Cancer Res 10:3265\u20133272","journal-title":"Clin Cancer Res"},{"issue":"12","key":"4578_CR17","first-page":"3710","volume":"8","author":"EH Rubin","year":"2002","unstructured":"Rubin EH, de Alwis DP, Pouliquen I et al (2002) A phase I trial of a potent P-glycoprotein inhibitor, Zosuquidar.3HCl trihydrochloride (LY335979), administered orally in combination with doxorubicin in patients with advanced malignancies. Clin Cancer Res 8(12):3710\u20133717","journal-title":"Clin Cancer Res"},{"issue":"7","key":"4578_CR18","first-page":"782","volume":"89","author":"G Gerrard","year":"2004","unstructured":"Gerrard G, Payne E, Baker RJ et al (2004) Clinical effects and P-glycoprotein inhibition in patients with acute myeloid leukemia treated with zosuquidar trihydrochloride, daunorubicin and cytarabine. Haematologica 89(7):782\u2013790","journal-title":"Haematologica"},{"key":"4578_CR19","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s00280-004-0775-4","volume":"54","author":"S Callies","year":"2004","unstructured":"Callies S, de Alwis DP, Mehta A, Burgess M, Aarons L (2004) Population pharmacokinetic model for daunorubicin and daunorubicinol coadministered with zosuquidar.3HCl (LY335979). Cancer Chemo Pharmacol 54:39\u201348","journal-title":"Cancer Chemo Pharmacol"},{"key":"4578_CR20","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1016\/j.leukres.2008.09.015","volume":"33","author":"JE Lancet","year":"2009","unstructured":"Lancet JE, Baer MR, Duran GE, List AF, Fielding R, Marcelletti JF, Multani PS, Sikic BI (2009) A phase I trial of continuous infusion of the multidrug resistance inhibitor Zosuquidar with Daunorubicin and Cytarabine in Acute Myeloid Leukemia. Leuk Res 33:1055\u20131061","journal-title":"Leuk Res"},{"issue":"4","key":"4578_CR21","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1182\/blood.V98.4.988","volume":"98","author":"ML Linenberger","year":"2001","unstructured":"Linenberger ML, Hong T, Flowers D et al (2001) Multidrug-resistance phenotype and clinical responses to gemtuzumab ozogamicin. Blood 98(4):988\u2013994","journal-title":"Blood"},{"key":"4578_CR22","first-page":"1490","volume":"7","author":"PF Bross","year":"2001","unstructured":"Bross PF, Beitz J, Chen G et al (2001) Report from the FD: approval summary: gemtuzumab ozogamicin in relapsed acute Myeloid Leukemia. Clin Cancer Res 7:1490\u20131496","journal-title":"Clin Cancer Res"},{"key":"4578_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1634\/theoncologist.2017-0604","volume":"23","author":"KJ Norsworthy","year":"2018","unstructured":"Norsworthy KJ, Ko C-W, Lee JE, Liu J, John CS, Przepiorka D, Farrell AT, Pazdup R (2018) FDA approval summary: mylotarg for treatment of patients with relapsed or refractory CD33-positive acute Myeloid Leukemia. Oncologist 23:1\u20136","journal-title":"Oncologist"},{"key":"4578_CR24","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.3892\/ijo_00000638","volume":"36","author":"M Cianfriglia","year":"2010","unstructured":"Cianfriglia M, Mallano A, Ascione A, Dupuis ML (2010) Multidrug transporter proteins and cellular factors involved in free and mAb linked calicheamicin-\u00c11 (gentuzumab ozogamicin, GO) resistance and in the selection of GO resistant variants of the HL60 AML cell line. Intl J Oncol 36:1513\u20131520","journal-title":"Intl J Oncol"},{"key":"4578_CR25","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1038\/sj.leu.2401851","volume":"14","author":"K Naito","year":"2000","unstructured":"Naito K, Takeshita A, Shigeno K, Nakamura S, Fujisawa S, Shinjo K, Yoshida H, Ohnishi K, Mori M, Terakawa S, Ohno R (2000) Calicheamicin-conjugated humanized anti-CD33 monoclonal antibody (gemtuzumab ozogamicin, CMA-676) shows cytocidal effect on CD33-positive leukemia cell lines, but is inactive on P-glycoprotein-expressing sublines. Leukemia 14:1436\u20131443","journal-title":"Leukemia"},{"issue":"8","key":"4578_CR26","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/1471-2407-8-51","volume":"13","author":"R Tang","year":"2008","unstructured":"Tang R, Faussat AM, Perrot JY, Marjanovic Z, Cohen S, Storme T, Morjani H, Legrand O, Marie JP (2008) Zosuquidar restores drug sensitivity in P-glycoprotein expressing acute myeloid leukemia (AML). BMC Cancer 13(8):51. https:\/\/doi.org\/10.1186\/1471-2407-8-51","journal-title":"BMC Cancer"},{"key":"4578_CR27","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1016\/S0006-2952(01)00599-8","volume":"61","author":"LJ Green","year":"2001","unstructured":"Green LJ, Marder P, Slapak CA (2001) Modulation by LY335979 of P-glycoprotein function in multidrug-resistant cell lines and human natural killer cells. Biochem Pharmacol 61:1393\u20131399","journal-title":"Biochem Pharmacol"},{"key":"4578_CR28","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1016\/j.leukres.2008.09.020","volume":"33","author":"JF Marcelletti","year":"2009","unstructured":"Marcelletti JF, Multani PS, Lancet JE, Baer MR, Sikic BI (2009) Leukemic blast and natural killer cell P-glycoprotein function and inhibition in a clinical trial of zosuquidar infusion in acute myeloid leukemia. Leuk Res 33:769\u2013774","journal-title":"Leuk Res"},{"issue":"1","key":"4578_CR29","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1002\/cyto.b.21737","volume":"96","author":"JF Marcelletti","year":"2019","unstructured":"Marcelletti JF, Paietta E, Sikic BI (2019) Evidence of a role for functional heterogeneity in multidrug resistance (MDR) transporters in clinical trials of P-glycoprotein modulation in acute myeloid leukemia. Cytometry B Clin Cytom 96(1):57\u201366. https:\/\/doi.org\/10.1002\/cyto.b.21737","journal-title":"Cytometry B Clin Cytom"},{"key":"4578_CR30","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1200\/JCO.1990.8.5.813","volume":"8","author":"BD Cheson","year":"1990","unstructured":"Cheson BD, Cassileth PA, Head DR et al (1990) Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia. J Clin Oncol 8:813\u2013819","journal-title":"J Clin Oncol"},{"key":"4578_CR31","unstructured":"National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology. Acute myeloid Leukemia. Version 1.2022. https:\/\/www.nccn. org\/professionals\/physician_gls\/pdf\/aml.pdf (2020)"},{"key":"4578_CR32","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1002\/cncr.21326","volume":"104","author":"R Larson","year":"2005","unstructured":"Larson R, Sievers E, Stadtmauer EA et al (2005) Final report of the efficacy and safety of Gemtuzumab Ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence. Cancer 104:1442\u20131452","journal-title":"Cancer"},{"key":"4578_CR33","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1038\/sj.leu.2404434","volume":"21","author":"A-L Taksin","year":"2007","unstructured":"Taksin A-L, Legrand O, Raffoux E et al (2007) High efficacy and safety profile of fractionated doses of Mylotarg as induction therapy in patients with relapsed acute myeloblastic leukemia: a prospective study of the alfa group. Leukemia 21:66\u201371","journal-title":"Leukemia"},{"issue":"20","key":"4578_CR34","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1182\/blood-2010-09-304311","volume":"116","author":"E Libby","year":"2010","unstructured":"Libby E, Hromas R (2010) Dismounting the MDR horse Comment on Cripe et al. Blood 116(20):4\u20135","journal-title":"Blood"},{"key":"4578_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/20406207231154708","volume":"14","author":"M Swaminathan","year":"2023","unstructured":"Swaminathan M, Cortes JE (2023) Update on the role of gemtuzumab ozogamicin in the treatment of acute myeloid leukemia. Ther Adv Hematol 14:1\u201310. https:\/\/doi.org\/10.1177\/20406207231154708","journal-title":"Ther Adv Hematol"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-023-04578-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00280-023-04578-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-023-04578-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,15]],"date-time":"2023-09-15T04:04:56Z","timestamp":1694750696000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00280-023-04578-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,21]]},"references-count":35,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["4578"],"URL":"https:\/\/doi.org\/10.1007\/s00280-023-04578-9","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,21]]},"assertion":[{"value":"17 May 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"No animals were involved in this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research involving animals"}}]}}